The Pen needles market in North America is expected to reach USD 1.06 billion by 2027 from USD 0.64 billion in 2022, growing at a CAGR of 10.60% from 2022 to 2027.
The growing occurrences of chronic diseases and illness, mainly diabetes, cancers, cardiovascular issues, raise demand for the pen needles market. The ever increasing geriatric population, spread rate of infections, increase in the number of people who have diabetes, type 1, and type 2 lead to market growth. In recent times besides syringes and minimally invasive devices, vials; pen needles are more preferred, which drives demand for the availability and usage of pen needles. Growing awareness in people about self-checking or testing and self-medication, administering the drug in insulin therapy by patients with diabetes type 1 and type 2 increases market size.
Technological advancements, more R & D activities, innovative ideas for designing more medical devices with high patient compliance, focus shifts on patients' pain management increase market size. Other factors, such as the adaption of minimally invasive surgeries and the rise in public awareness for a healthy lifestyle, government’s healthcare benefits and schemes, and easy commute to hospitals, clinics, and health centers, increase market size. The rise in global investors, rise in economy, and spending on this market increased government and public funding to improve the pen needles market.
On the other hand, there are few market restraints faced by this market, which will hinder the growth of the pen needles market in this region. Factors such as safety concerns, pain management inpatient population, focus shift on patient compliance, and other potential reasons effects market size. The rise in preference of other alternative techniques restricts the pen needles market to grow. Needlestick injuries, reuse of pen needles are the main concerns for this market to grow.
COVID 19 cases all around the world are rising. The shortage of minimal medical devices and other needed medical essential supplies are seen during recent times. In order to prevent widespread infections, there is more demand for these medical devices and supplies. An increase in the number of cases, the spread of disease, and the death toll is observed in recent times. More critical care is required for a patient population in severe condition and is on ventilators, for which more medical staff and professionals are also needed to assist. Social distancing is the only way to eradicate the spread of coronavirus.
This research report on the North America Pen Needles Market has been segmented and sub-segmented into the following categories:
Based on geographical areas, The U.S. is estimated to account for a larger share of the North America pen needles market in 2019. In contrast, Canada is estimated to grow at a higher CAGR during the forecast period.
North America is expecting steady growth in the pen needles market during the forecast period. Factors such as rise in the geriatric population, favorable healthcare economy, spending, reimbursement plans, rise in chronic diseases, rise in demand for standards and safety, and advancement in inpatient population safety concerns increase market size.
The United States stands first for well-developed technology and research activities for the medical devices market. Canada, with its highest recorded patients suffering from various illnesses, increases market size. The adaption of pen needles by the diabetic population is a major driving factor for this market. According to reports by the CDC, 100 million people are suffering from diabetes and pre-diabetes. Hence the need for pen needles in the process of treatment and procedures increases the market size.
Companies like Becton Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), UltiMed, Inc. (U.S.), Allison Medical, Inc. (U.S.), Owen Mumford, Ltd. (U.K.), B. Braun Melsungen (Germany), Artsana S.p.a. (Italy), HTL-STREFA S.A. (Poland), Terumo Corporation (Japan) are leading the North American Pen Needles Market.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1.2 Insulin Therapy
5.1.3 GLP-1 Therapy
5.1.4 Growth Hormone Therapy Growth Hormone Therapy
5.2.2 Standard Needle
5.2.3 Safety Needle
5.3 Needle Length
5.4 Mode of Purchase
6.2 United States
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Becton, Dickinson and Company (U.S.)
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Ypsomed Holding AG (Switzerland)
8.4 UltiMed, Inc. (U.S.)
8.5 Allison Medical, Inc. (U.S.)
8.6 Owen Mumford, Ltd. (U.K.)
8.7 B. Braun Melsungen (Germany)
8.8 Artsana S.p.a. (Italy)
8.9 HTL-STREFA S.A. (Poland)
8.10 Terumo Corporation (Japan)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.